

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/080,529
Filing Date	February 21, 2002
First Named Inventor	STRAUSS, H. WILLIAM
Group Art Unit	Unassigned
Examiner Name	Unassigned
Total Number of Pages in This Submission	Attorney Docket Number 020039-001510US

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Fee Authorization (IDS page 2) 31 Reference Copies
Remarks		The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name	Townsend and Townsend and Crew LLP Craig P. Wong	Reg. No. 45,231
Signature		
Date	10.2.02	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name	Edward Masinas		
Signature		Date	10.2.02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. PA 3254218 v1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT

Attorney Docket No.: 020039-001510US

Assistant Commissioner for Patents
Washington, D.C. 20231



On 10.2.02

TOWNSEND and TOWNSEND and CREW LLP

By: Edward Masinas
Edward Masinas

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

H. WILLIAM STRAUSS

Application No.: 10/080,529

Filed: February 21, 2002

For: METHODS AND SYSTEMS
WHICH USE ANNEXIN FOR
BIOPROFILING BODY LUMEN

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Craig P. Wong
Reg. No. 45,231

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
CPW:bjl
PA 3254210 v1



Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of

Application Number	10/080,529
Filing Date	February 21, 2002
First Named Inventor	H. WILLIAM STRAUSS
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	020039-001510US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	AA	US 4,647,445		03/03/1987	Lees	
	AB	US 4,660,563		04/28/1987	Lees	
	AC	US 4,877,599		10/31/1989	Lees	
	AD	US 4,937,067		06/26/1990	Lees	
	AE	US 5,429,133		07/04/1995	Thurston, et al.	
	AF	US 5,510,466		04/23/1996	Krieger et al.	
	AG	US 5,627,036		05/06/1997	Reutelingsperger	
	AH	US 5,711,931		01/27/1998	Dean et al.	
	AI	US 5,716,595		02/10/1998	Goldenberg	
	AJ	US 5,726,153		03/10/1998	Lees et al.	
	AK	US 5,811,814		09/22/1998	Leone et al.	
	AL	US 5,968,477		10/19/1999	Kasina et al.	
	AM	US 6,171,577		01/9/2001	Kasina et al.	
	AN	US 6,197,278		03/06/2001	Blankenberg et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	AO	PCT	WO 89/10760	11/16/1989			<input type="checkbox"/>

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AP	D'ARCEUIL, et al., ^{99m} Tc Annexin V Imaging of Neonatal Hypoxic Brain Injury, <i>Stroke</i> , Nov. 2000, pp. 2692-2700.	
	AQ	DEMOS, et al., In Vitro Targeting of Antibody-Conjugated Echogenic Liposomes for Site-Specific Ultrasonic Image Enhancement, <i>J. Pharmaceutical Sciences</i> , Vol. 86, No. 2, Feb. 1997.	
	AR	ELMALEH, et al., Rapid noninvasive detection of experimental atherosclerotic lesions with novel ^{99m} Tc-labeled diadenosine tetraphosphates, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 95, pp. 6910695, Jan. 1998.	
	AS	FADOK, et al., A receptor for phosphatidylserine-specific clearance of apoptotic cells, <i>Nature</i> , Vol. 405, May 2000, pp. 85-90.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of

Application Number	10/080,529
Filing Date	February 21, 2002
First Named Inventor	H. WILLIAM STRAUSS
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	020039-001510US

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	AT		GIDON-JEANGIRARD, et al., Annexin V Delays Apoptosis While Exerting an External Constraint Preventing the Release of CD4+ and PrP ^C Membrane Particles in a Human T Lymphocyte Model, <i>J. Immunology</i> , 1999, 162:5712-5718.				
	AU		GIDON-JEANGIRARD, et al., Annexin V Counteracts Apoptosis While Inducing Ca ²⁺ Influx in Human Lymphocytic T Cells, <i>Biochemical and Biophysical Research Communications</i> , Vol. 265, No. 3, 1999, pp. 709-715.				
	AV		HAMMILL, et al., Annexin V Staining Due to Loss of Membrane Asymmetry Can Be Reversible and Precede Commitment to Apoptotic Death, <i>Experimental Cell Research</i> 251, 16-21 (1999).				
	AW		LEES, et al., Imaging Human Atherosclerosis with ^{99m} Tc-labeled Low Density Lipoproteins, <i>Arteriosclerosis</i> 8:461-470, Sept/Oct. 1988).				
	AX		NARULA, et al., Noninvasive Localization of Experimental Atherosclerotic Lesions With Mouse/Human Chimeric Z2D3 F(ab) ₂ Specific for the Proliferating Smooth Muscle Cells of Human Atheroma, <i>Circulation</i> , 1995; 92:474-484.				
	AY		NARULA, et al., Transient Sarcolemmal Phosphatidyl Serine Expression as a Marker of Brief Ischemia: an Evaluation by ^{99m} Tc-Annexin-V Imaging, <i>Proc. of the 47th Annual Meeting</i> , Vol. 41, No. 5, May 2000 supplement, p. 173P				
	AZ		RUSSO-MARIE, Annexin V. and Phospholipid Metabolism, <i>Clin Chem Lab Med</i> , 1999; 37(3):287-291, 1999 by Walter de Gruyter, Berlin/New York.				
	BA		STRATTON, et al., Selective Uptake of Radiolabeled Annexin V on Acute Porcine Left Atrial Thrombi, <i>Circulation</i> 1995; 92:3113-3121.				
	BB		STRAUSS, et al., Radioimaging to identify myocardial cell death and probably injury, <i>The Lancet</i> , Vol. 358, July 15, 2000.				
	BC		VALLABHAJOSULA and FUSTER, Atherosclerosis: Imaging Techniques and the Evolving Role of Nuclear Medicine, <i>J. Nuclear Medicine</i> , Vol. 38, No. 11, Nov. 1997.				
	AD		ZWALL and SCHROIT, Pathophysiologic Implications of Membrane Phospholipid Asymmetry in Blood Cells, <i>Blood</i> , Vol. 89, No. 4, Feb. 15, 1987, pp. 1121-1132.				
	AE		PET PROBE TM Surgical Radiation Detection System for Positrons & 511keV Gamma Rays, http://www.intra-medical.com/IMI/pprobe.html .				

PA 3254210 v1

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.